$NIKA
Nika Pharmaceuticals Inc

2024 Q1 Form 10-K Financial Statement

#000182646624000041 Filed on April 01, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $65.99K $64.83K
YoY Change 237.19% -97.96%
Operating Profit -$65.99K -$64.83K
YoY Change -437.19% -97.96%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$65.99K -$64.83K
YoY Change -437.19% -97.96%
Income Tax
% Of Pretax Income
Net Earnings -$65.99K -$64.83K
YoY Change -437.19% -97.96%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00
COMMON SHARES
Basic Shares Outstanding 876.1M shares 876.1M shares
Diluted Shares Outstanding 876.1M shares

Balance Sheet

Concept 2024 Q1 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $24.47K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory $17.01K
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $41.47K
YoY Change 830.1%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $41.47K
Total Long-Term Assets $0.00
Total Assets $41.47K
YoY Change 830.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $256.6K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $266.0K
YoY Change 543.26%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $266.0K
Total Long-Term Liabilities
Total Liabilities $266.0K
YoY Change 543.26%
SHAREHOLDERS EQUITY
Retained Earnings -$8.931M
YoY Change 166.2%
Common Stock $87.61K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$224.5K
YoY Change
Total Liabilities & Shareholders Equity $41.47K
YoY Change 830.1%

Cashflow Statement

Concept 2024 Q1 2023
OPERATING ACTIVITIES
Net Income -$65.99K -$64.83K
YoY Change -437.19% -97.96%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$150.0K $64.83K
YoY Change 666.52% 92.3%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $154.9K $83.57K
YoY Change 568.58% 144.49%
NET CHANGE
Cash From Operating Activities -$150.0K $64.83K
Cash From Investing Activities
Cash From Financing Activities $154.9K $83.57K
Net Change In Cash $4.870K $18.73K
YoY Change 35.47% 3928.39%
FREE CASH FLOW
Cash From Operating Activities -$150.0K $64.83K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023 us-gaap Business Development
BusinessDevelopment
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
usd
CY2023 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
usd
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2022 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
CY2023 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2023 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001145604
CY2024Q1 dei Entity Public Float
EntityPublicFloat
0 usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023 us-gaap Adjustments To Additional Paid In Capital Stock Issued Ownshare Lending Arrangement Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts
usd
CY2023 us-gaap Dividend Payable Date To Be Paid Day Month And Year
DividendPayableDateToBePaidDayMonthAndYear
2022-07-20
CY2023 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
usd
CY2022 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
usd
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
000-56234
CY2023 dei Entity Registrant Name
EntityRegistrantName
NIKA PHARMACEUTICALS, INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
CO
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
90-0292940
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
2269 Merrimack Valley Avenue
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Henderson
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
NV
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
89044
CY2023 dei City Area Code
CityAreaCode
(702)
CY2023 dei Local Phone Number
LocalPhoneNumber
326-3615
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
876090000 shares
CY2023 dei Auditor Firm
AuditorFirmId
5525
CY2022 dei Auditor Firm
AuditorFirmId
5041
CY2023 dei Auditor Name
AuditorName
Fruci & Associates II, PLLC
CY2023 dei Auditor Location
AuditorLocation
Spokane
CY2022 dei Auditor Name
AuditorName
BF Borgers CPA PC
CY2022 dei Auditor Location
AuditorLocation
Lakewood
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19596 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
864 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
19596 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
864 usd
CY2023Q4 us-gaap Assets
Assets
19596 usd
CY2022Q4 us-gaap Assets
Assets
864 usd
CY2023Q4 us-gaap Debt Current
DebtCurrent
101745 usd
CY2022Q4 us-gaap Debt Current
DebtCurrent
18180 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
101745 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18180 usd
CY2023Q4 us-gaap Liabilities
Liabilities
101745 usd
CY2022Q4 us-gaap Liabilities
Liabilities
18180 usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
10000000 shares
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
1000 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
1000 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2700000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2700000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
876090000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
876090000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
876090000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
876090000 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
87609 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
87609 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3229489 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3229489 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3400247 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3335414 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-82149 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-17316 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19596 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
864 usd
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
64833 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
33715 usd
CY2022 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
150000 usd
CY2022 us-gaap Business Development
BusinessDevelopment
3000000 usd
CY2023 us-gaap Operating Expenses
OperatingExpenses
64833 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
3183715 usd
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-64833 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-3183715 usd
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-64833 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3183715 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-64833 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-3183715 usd
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
876090000 shares
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
723953014 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-23619 usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Stock Issued Ownshare Lending Arrangement Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts
30018 usd
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10000 usd
CY2022 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
150000 usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock
AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
3000000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-3183715 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-17316 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-64833 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-82149 usd
CY2023 us-gaap Profit Loss
ProfitLoss
-64833 usd
CY2022 us-gaap Profit Loss
ProfitLoss
-3183715 usd
CY2022 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
3000000 usd
CY2022 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
150000 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
64833 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
33715 usd
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10000 usd
CY2023 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
83565 usd
CY2022 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
24180 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
83565 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
34180 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
18732 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
465 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
864 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
399 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19596 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
864 usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Stock Issued Ownshare Lending Arrangement Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts
30018 usd
CY2023 us-gaap Business Acquisition Planned Restructuring Activities Description
BusinessAcquisitionPlannedRestructuringActivitiesDescription
As a result of the purchase by Dimitar Slavchev Savov of a total of 11,489,000 (87%) shares of common stock of the Corporation from Mr. Ray and other shareholders, a change in control of the Company occurred as of April 1, 2022.
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84B_eus-gaap--UseOfEstimates_zjhU00mQsSf9" style="text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_86C_z8A0KPE6uBoi">Use of Estimates</span></span></i><i> </i></p> <p style="text-align: justify">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. </p>
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zLley7Rofcu2" style="text-align: justify"><i><span style="text-decoration: underline"><span id="xdx_868_zQg7nsqUSPF6">Concentrations of Credit Risk</span></span></i> </p> <p style="text-align: justify">We maintain our cash in bank deposit accounts, the balances of which at times may exceed federally insured limits. We continually monitor our banking relationships and consequently have not experienced any losses in our accounts. We believe we are not exposed to any significant credit risk on cash. </p>
CY2023Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0.0001
CY2022Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
30000000 shares
CY2022Q2 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
10000 usd
CY2022Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
0.00033
CY2023Q4 us-gaap Cumulative Earnings Deficit
CumulativeEarningsDeficit
3400247 usd
CY2023 us-gaap Revenues
Revenues
0 usd
CY2023 us-gaap Substantial Doubt About Going Concern Managements Evaluation
SubstantialDoubtAboutGoingConcernManagementsEvaluation
Company has an accumulated deficit of $3,382,790 as of June 30, 2023, has no current operations and has generated no income to date. These factors raise substantial doubt about its ability to continue as a going concern.
CY2023 us-gaap Substantial Doubt About Going Concern Managements Plans Substantial Doubt Alleviated
SubstantialDoubtAboutGoingConcernManagementsPlansSubstantialDoubtAlleviated
Company may raise additional capital through the sale of its equity securities, through offerings of debt securities, or through borrowings from financial institutions.
CY2023 us-gaap Notes Reduction
NotesReduction
30018 usd
CY2023 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
30018 usd
CY2023 us-gaap Common Stock Dividends Shares
CommonStockDividendsShares
846887000 shares
CY2022Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0.001
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2023 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-14000 usd
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-669000 usd
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
14000 usd
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
669000 usd
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Contingencies State And Local
EffectiveIncomeTaxRateReconciliationTaxContingenciesStateAndLocal
0.21 pure
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
714000 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
700000 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
714000 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
700000 usd
CY2022Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
714000 usd
CY2023 dei Entity Listing Description
EntityListingDescription
As of January 25, 2024, the Company’s common stock is listed on OTC Markets PINK under the symbol, NKPH
CY2023 us-gaap Subsequent Event Description
SubsequentEventDescription
On March 4, 2024, the Company amended its Articles of Incorporation in which the authorized Preferred Stock was increased to 15,000,000 pursuant to the approved by the BOD and shareholders Plan and Merger Agreement

Files In Submission

Name View Source Status
0001826466-24-000041-index-headers.html Edgar Link pending
0001826466-24-000041-index.html Edgar Link pending
0001826466-24-000041.txt Edgar Link pending
0001826466-24-000041-xbrl.zip Edgar Link pending
exhibit31-1.htm Edgar Link pending
exhibit32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-k.htm Edgar Link pending
image_001.jpg Edgar Link pending
image_logo.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
nkph-20231231.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
nkph-20231231_cal.xml Edgar Link unprocessable
nkph-20231231_def.xml Edgar Link unprocessable
nkph-20231231_lab.xml Edgar Link unprocessable
nkph-20231231_pre.xml Edgar Link unprocessable
form10-k_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable